直接測試不同腫瘤細胞內bG-activities, 不同腫瘤細胞間內生性bG-的活性並不相同, 異體移植不同細胞的腫瘤間內生性bG-的活性也不相同, 切片測試和活體照影的結果並不致.利用葡萄醣醛酸造影劑活體評估葡萄醣酸前驅藥物(9-ACG)和CPT-11之標靶治療的療效, 以NIR-TrapG評估bG活性, 與9ACGM的治療效果呈正相關, 另外, 造影劑有bG-活性表現的腫瘤colon 205, 當以CPT-11治療時, 對腫瘤生長的抑制作用比沒有bG-活性表現的腫瘤HCT116明顯有效. In vivo imaging to detect the endogenous b-glucuronidase activity, these have difference amounts of b-glucuronidase activity. Evaluate the therapeutic effect of glucuronide prodrug (9-ACG) in colon tumor, its effect equal with b-glucuronidase activity. Evaluate the therapeutic effect of glucuronide prodrug (CPT-11) in colon tumor with different b-glucuronidase activity, it is efficiency against tumor with highly b-glucuronidase activity than less level.
